Novabay Pharmaceuticals (NBY) |
|
0.6404 -0.015 (-2.24%)
|
07-29 04:15 |
|
Open: |
0.6495 |
Pre. Close: |
0.6551 |
|
High:
|
0.6849 |
Low:
|
0.6305 |
|
Volume:
|
2,584,945 |
Market Cap:
|
27M |
|
|
|
|
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.681 - 0.684 |
0.684 - 0.687 |
|
Low:
|
0.621 - 0.625 |
0.625 - 0.629 |
|
Close:
|
0.633 - 0.639 |
0.639 - 0.645 |
|
Technical analysis |
as of: 2021-07-28 4:45:57 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.81 One year: 0.90 |
| Support: |
Support1: 0.56 Support2: 0.47 |
| Resistance: |
Resistance1: 0.69 Resistance2: 0.77 |
| Pivot: |
0.62  |
| Moving Average: |
MA(5): 0.64 MA(20): 0.63
MA(100): 0.77 MA(250): 0.81 |
| MACD: |
MACD(12,26): -0.01 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 41.97 %D(3): 45.95 |
| RSI: |
RSI(14): 49.11 |
| 52-week: |
High: 1.79 Low: 0.52 Change(%): -45.3 |
| Average Vol(K): |
3-Month: 165949 10-Days: 533247 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.NBY has closed below upper band by 32.9%. Bollinger Bands are 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to NBY's normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 28 Jul 2021
Novabay (NBY) falls 2.24% to Close at $0.64 on July 28 - Equities.com
Wed, 28 Jul 2021
NovaBay Pharmaceuticals Inc. (NBY) stock is likely to drive top-line growth - BOV News
Tue, 27 Jul 2021
NovaBay Pharmaceuticals, Inc. (NBY) Stock Gains 24.14% This Week: Is It a Good Pick? - InvestorsObserver
Tue, 27 Jul 2021
NovaBay Pharmaceuticals Inc. (AMEX: NBY) Disappoints Wall Street With -1.45% Stock Price Loss - Marketing Sentinel
Tue, 27 Jul 2021
Novabay (NBY) falls 1.45% to Close at $0.62 on July 26 - Equities.com
Fri, 23 Jul 2021
A -392.42% Or Greater Growth Is Projected For NovaBay Pharmaceuticals Inc. (AMEX: NBY) - Marketing Sentinel
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
42 |
| Shares Float (M) |
33 |
|
% Held by Insiders
|
41.27 |
|
% Held by Institutions
|
6.53 |
|
Shares Short (K)
|
515 |
|
Shares Short P. Month (K)
|
546 |
Stock Financials |
|
EPS
|
-0.361 |
|
EPS Est This Year
|
-0.470 |
|
EPS Est Next Year
|
-0.090 |
|
Book Value (p.s.)
|
0.030 |
|
Profit Margin
|
-97.79 |
|
Operating Margin
|
-68.19 |
|
Return on Assets (ttm)
|
-34.0 |
|
Return on Equity (ttm)
|
-681.2 |
|
Qtrly Rev. Growth
|
122.7 |
|
Gross Profit (p.s.)
|
0.116 |
|
Sales Per Share
|
0.221 |
|
EBITDA (p.s.)
|
-0.149 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-5 |
|
Levered Free Cash Flow (M)
|
-2 |
Stock Valuations |
|
PE Ratio
|
-1.77 |
|
PEG Ratio
|
|
|
Price to Book value
|
21.35 |
|
Price to Sales
|
2.89 |
|
Price to Cash Flow
|
-5.53 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
